stock · yahoo

Elevance Health, Inc.

ELV

$407.50
7.28 (-1.76%)
polled · warming up

Below: live stock price for Elevance Health, Inc. (ELV), a 1-year chart, 8 indicators (RSI, MACD, Bollinger, MA, EMA, Stochastic, ATR, Volume), and a compare mode. Add to your portfolio, star to your watchlist, or set a price alert in one place.

Elevance Health, Inc. (ELV) is a Healthcare company based in United States. Operating in Healthcare Plans, it employs about 96,129 people. Over the past year ELV traded between 274.84 and 436.24 USD. Trailing P/E sits near 18.35 on a market cap of about 88.37B USD. It currently yields 1.66% in dividends.

Day
-1.76%
-7.28
Week
+3.31%
+13.07
Month
+4.16%
+16.26
Year
Prev close
$414.78
Volume (24h)
$424.59M
Market cap
$88.37B
Currency
USD

Score

52/ 100 · Mixed

Coverage: 7/7
  • Value69
  • Quality35
  • Momentum55
  • Growth24
  • Risk78
  • Dividend56
  • Liquidity44

Composite of public market data. Informational only — not investment advice.

Trend projection

Where the recent trend points if it continues.

SidewaysFit 0%Pace -0.00% per bar
+5 bars+20 bars+60 bars+120 bars
+5 bars
407.4809
-0.00%
Bull473.3805
Bear350.7553
+20 bars
407.4547
-0.01%
Bull549.9022
Bear301.907
+60 bars
407.4445
-0.01%
Bull684.8447
Bear242.4068
+120 bars
407.4441
-0.01%
Bull849.1936
Bear195.4922

Linear-regression continuation — not a prediction, not investment advice. ±1σ ≈ 68% range · ±2σ ≈ 95% range: ±0.0335 USD.

Interpretation

Composite signals look mixed. Strength: risk profile with weakness: growth. Price sits in the middle of the recent range, trend is roughly flat.

Descriptive observation — not investment advice.

Score breakdown

Raw values behind each pillar so you can see what the composite is reading.

  • Value
    69/100

    Value looks solid — driven by P/E (18.35).

    P/E:18.35P/B:1.97PEG:1.36
  • Quality
    35/100

    Quality looks weak — driven by Gross margin (25.99%).

    ROE:11.13%ROA:3.83%Profit margin:2.47%Gross margin:25.99%
  • Momentum
    55/100

    Momentum looks mixed — driven by 52w change (32.25%).

    52w change:32.25%
  • Growth
    24/100

    Growth looks fragile — driven by Earnings growth (-13.10%).

    Revenue growth:1.40%Earnings growth:-13.10%
  • Risk
    78/100

    Risk looks strong — driven by Debt / equity (68.95).

    Beta:0.7Debt / equity:68.95Short interest:2.79%
  • Dividend
    56/100

    Dividend looks mixed — driven by Payout ratio (30.34%).

    Dividend yield:1.66%Payout ratio:30.34%
  • Liquidity
    44/100

    Liquidity looks weak — driven by Current ratio (1.52).

    Current ratio:1.52Quick ratio:1.37

Derived from public market data — informational, not investment advice.

Price report

How this asset has actually moved over the last 252 days.

Position in range82%
274.84 low436.24 high

Where the price sits between the window low and high.

Volatility (annualised)
35.6%

Spread of returns. Higher means larger swings in both directions.

Max drawdown
-26.5%

Worst peak-to-trough fall inside the window.

Below period high
-6.6%

Current price against the highest point in the window.

Best day
+7.62%
Worst day
-14.33%
Up days
53%

Share of days that closed above the one before.

Current streak
1 down
Typical day swing
2.8%

Average high-to-low spread within a single day.

Volume vs average
-37%

Last 10 days against the whole window.

Descriptive statistics over past prices — not a forecast and not investment advice.

Reference levels

Fibonacci retracements and extensions across the recent range.

60 bars

Reference only — not investment advice.

These coordinates describe past-trade clustering, not where to buy or sell. Do your own research before any trade.

Next level above
408.2547 USD+0.19%
Fib 38.2% retracement
Next level below
399.61 USD-1.94%
Fib 50% midpoint

Levels derived from: 436.24 high 362.98 low · 60 bars

  • Resistance
    Fib +161.8% extension
    not reached
    554.7746 USD
    +36.14% from current
  • Resistance
    Fib +100% extension
    not reached
    509.5 USD
    +25.03% from current
  • Resistance
    Fib +61.8% extension
    not reached
    481.5147 USD
    +18.16% from current
  • Resistance
    Fib +27.2% extension
    not reached
    456.1667 USD
    +11.94% from current
  • Resistance
    Fib 23.6% retracement
    tested 5×
    418.9506 USD
    +2.81% from current
  • Resistance
    Fib 38.2% retracementNearest
    tested 6×
    408.2547 USD
    +0.19% from current
  • Current
    407.5 USD
  • Support
    Fib 50% midpoint
    tested 19×
    399.61 USD
    -1.94% from current
  • Support
    Fib 61.8% retracement
    tested 19×
    390.9653 USD
    -4.06% from current
  • Support
    Fib 78.6% retracement
    tested 13×
    378.6576 USD
    -7.08% from current
  • Support
    Fib −27.2% extension
    not reached
    343.0533 USD
    -15.82% from current
  • Support
    Fib −61.8% extension
    not reached
    317.7053 USD
    -22.04% from current
  • Support
    Fib −100% extension
    not reached
    289.72 USD
    -28.90% from current
How to read this

We take the highest and lowest price of the last 60 bars and cut the gap between them at the classic Fibonacci ratios (23.6%, 38.2%, 50%, 61.8%, 78.6%), plus extensions beyond both ends.

“Tested N×” counts how many of those 60 bars actually traded through the level. A level price has crossed many times is one the market has repeatedly agreed on; a level at 0 is pure geometry the price has never reached.

This is a map of where trading has already happened — not a forecast and not a signal. Price moves through these levels all the time.

Financials

52w high
$436.24
52w low
$274.84
52w change
32.25%
Day high
$414.46
Day low
$406.34
P/E (TTM)
18.35
Forward P/E
13.76
PEG
1.36
Price / Book
1.97
Beta (5Y)
0.7
Enterprise value
82.04B
EV / Revenue
0.41
EV / EBITDA
9.86
EPS (TTM)
$22.21
Forward EPS
$29.61
Dividend yield
1.66%
Dividend rate
$6.88
Payout ratio
30.34%
Revenue (TTM)
201.11B
EBITDA
8.32B
Free cash flow
4.31B
Total cash
37.51B
Total debt
31.04B
Debt / Equity
68.95
Current ratio
1.52
Quick ratio
1.37
Profit margin
2.47%
Gross margin
25.99%
Return on assets
3.83%
Return on equity
11.13%
Shares outstanding
216.87M
Float
216.37M
Sector: HealthcareIndustry: Healthcare PlansHQ: United StatesEmployees: 96.13Kwww.elevancehealth.com

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to individual, employer group risk-based and fee-based, BlueCard, Medicare, Medicaid, and FEP members; health products; a broad array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, and supplemental health insurance benefits. The company also operates in the pharmacy services business; and markets and offers pharmacy services, including home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services, as well as infusion services and injectable therapies through ambulatory infusion centers. In addition, it provides healthcare related services and capabilities, including specialty care enablement and utilization management support for specialized clinical domains; behavioral health and comprehensive care management services; palliative care services and management; virtual care; and payment integrity, subrogation, clinical data exchange through its HealthOS platform, research and data, reporting and clinical analytics, information technology, and business process support services, as well as manages home health, post-acute institutional management, and durable medical equipment costs; and supports plans in managing home and community-based services. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brands. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is based in Indianapolis, Indiana.

Analyst & Risk

Consensus
Buy
Mean rating1.77 / 5
Analysts21
Next earnings2026-10-21
Strong buy 3Buy 12Hold 7
Analyst price target
$449.10
Mean target · 21 analysts
+10.2%
upside
Low $393.00Now $407.50High $492.00
Beta (vs S&P 500)
0.7
less volatile
52-week change
32.25%
Short % of float
2.79%
Short ratio (days)
3.97
Debt / Equity
68.95
very high leverage
Current ratio
1.52
Quick ratio
1.37
ROE
11.13%
ROA
3.83%
PEG ratio
1.36
fair
EV / Revenue
0.41
EV / EBITDA
9.86
Revenue growth
1.40%
Earnings growth
-13.10%
EBITDA
8.32B
Free cash flow
4.31B
Total cash
37.51B
Total debt
31.04B
Insider holdings
0.19%
Institutional
94.14%

Recent rating changes

  • 2026-07-17Leerink PartnersMarket PerformMarket Performmain
  • 2026-07-16RBC CapitalSector PerformSector Performmain
  • 2026-07-16Wells FargoOverweightOverweightmain
  • 2026-07-16GuggenheimBuyBuymain
  • 2026-07-16BarclaysOverweightOverweightmain
  • 2026-07-16BairdNeutralNeutralmain
  • 2026-07-14TD CowenBuyBuymain
  • 2026-07-14Truist SecuritiesBuyBuymain

Recent news

Related

Other assets in this category.

Live discussion

Sign in to join the discussion.

  • No comments yet. Be the first.